Intrexon acquires laboratory operations from Codexis

Intrexon (XON) announced that it has acquired state-of-the-art laboratory operations in Budapest, Hungary from Codexis (CDXS). The acquisition will expand Intrexon's strain and protein development capabilities, as well as strengthen fermentation process optimization and scale-up. Through the agreement, Intrexon's Industrial Products Division, or IPD, will absorb the Budapest laboratory staff of experienced scientific professionals. Integration of the Budapest team and their expertise with Intrexon's suite of synthetic biology technologies and capabilities will allow Intrexon to better serve current collaborators and to attract new opportunities for active pharmaceutical ingredients and industrial and consumer product collaborations.